On July 27, JOINN rose 6.46% in regular trading, trading at approximately 26.0 HKD/share, with turnover of approximately 53.59 million HKD. The rally was supported by multiple positive catalysts including institutional accumulation and broad CXO sector momentum.

According to Hong Kong Exchange equity disclosure filings, Barclays PLC increased its stake in JOINN by approximately 3.28 million shares on July 15 at approximately 24.25 HKD per share, with total consideration of approximately 79.54 million HKD. Following the purchase, Barclays' holding rose to approximately 7.29 million shares, representing a 6.12% stake in the company.

Concurrently, the Life Sciences Tools and Services sector continued its rebound trend. Within the sector, GenScript Biotech gained 3.04%, WuXi AppTec rose 1.33%, and WuXi Biologics added 1.33%, reflecting broad-based recovery in CXO industry sentiment. The company previously disclosed a half-year earnings forecast projecting net profit growth of 885% to 1,377% year-over-year, driven primarily by fair value appreciation of biological assets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)